Skip to main content
BMJ Public Health logoLink to BMJ Public Health
. 2025 Feb 22;3(1):e001128. doi: 10.1136/bmjph-2024-001128

Availability, prices and affordability of self-monitoring blood glucose devices: surveys in six low-income and middle-income countries

Margaret Ewen 1,✉, Molly Lepeska 1, Aida Abdraimova 2, Stéphane Besançon 3,4, Nguyen Thi Phuong Cham 5, Asel Dunganova 2, Moise Nguemeni 3, Lachlan Oldfield 6, Janeth Tenorio-Mucha 7, Hesty Utami Ramadaniati 8, Beatrice Vetter 9, David Beran 10
PMCID: PMC11865750  PMID: 40017936

Abstract

Introduction

Accessing glucose meters, test strips, lancets and continuous/flash glucose monitoring devices for self-monitoring blood glucose (SMBG) is crucial for the management of diabetes. Yet little is known about access to SMBG devices in low-income and middle-income countries.

Methods

In 2022/2023, facility-based surveys were undertaken in selected regions and sectors in Fiji, Indonesia, Kyrgyzstan, Mali, Peru and Vietnam. Availability and patient prices were collected in public sector outlets (hospital dispensaries/clinics) and private pharmacies in the community by in-person visits (except in Mali where it was collected by phone). Data were also collected in medical device shops (Vietnam), online marketplaces (Indonesia) and online from device manufacturers.

Availability was assessed as the percentage of outlets with the device in stock on the day of data collection. Median prices were calculated and reported in US dollars (US$). Affordability was assessed as the number of days’ wages needed by the lowest-paid unskilled government worker to purchase each device. The affordability of self-monitoring was then compared with that of insulin.

Results

SMBG devices were not generally provided to individuals for self-testing by governments in Fiji, Indonesia, Kyrgyzstan and Peru. Public sector availability ranged from 0% to 57% (meters) and 0% to 53% (strips). In private pharmacies, availability was 31% to 100% (meters) and 39% to 100% (strips). Some large regional variations were seen within countries. Median prices for one meter ranged from US$15.62 to US$35.18. For one strip, median prices ranged from US$0.27 to US$0.56. Continuous/flash glucose monitoring devices were only found online at US$88–US$107 per sensor. Between 1.5 and 10.9 days’ wages were needed to purchase 1 meter, and 1.0–12.8 days’ wages for 50 strips. Online purchases of 1-month supply of continuous/flash device sensors required 15–65 days’ wages. The cost of self-testing exceeded the cost of human insulin vials/syringes. However, analogue prefilled pens/pen needles were often higher priced than the cost of self-testing.

Conclusion

Poor availability and high prices were found for SMBG devices which can impact diabetes management. Prices of meters, test strips and sensors were unaffordable. Pricing for these essential tools requires further investigation including cost of goods sold; government procurement prices and volumes; and price components in supply chains. Accessing SMBG devices must not be considered in isolation to accessing insulin. Governments need to include SMBG devices in their package of essential diabetes services. They must also support ongoing monitoring to ensure people are accessing SMBG devices.

Keywords: Public Health, Public Health Practice, economics


WHAT IS ALREADY KNOWN ON THIS TOPIC

  • Self-testing of blood glucose levels is an essential component of diabetes management, especially for people living with type 1 diabetes.

  • The cost of self-monitoring is highly variable and can exceed the cost of human insulin.

  • Governments supplying insulin free of charge do not necessarily supply free self-testing devices.

WHAT THIS STUDY ADDS

  • Daily blood glucose testing at recommended levels can be unaffordable for people on low wages paying out-of-pocket in low-income and middle-income countries.

  • The cost of self-testing exceeded that of human insulin vials and syringes, but not always of analogue insulins in prefilled pens and pen needles.

  • Continuous/flash glucose monitoring devices were not found in outlets but could be purchased online in some countries from manufacturers and from other sources. Prices were unaffordable for those on low wages.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

  • Unaffordable prices of test strips need urgent investigation, including the cost of goods sold, government procurement prices and volumes, and price components (mark-ups, taxes, etc) in supply chains.

  • Manufacturers of continuous/flash glucose monitoring devices need to develop affordable, quality-assured devices that meet people’s needs, especially those living in low-income and middle-income countries.

  • Regular monitoring of availability, prices and affordability of self-monitoring blood glucose (SMBG) devices is needed, and assessing progress in achieving the WHO’s target of 100% of people with type 1 diabetes have access to affordable insulin and blood glucose self-monitoring.

  • Online marketplaces and medical device shops should be included in surveys where they are considered a common source of SMBG devices.

Introduction

In recent years, challenges in accessing diabetes treatment, in particular insulin, have gained global prominence with the United Nations General Assembly declaration and resolution on the prevention and control of non-communicable diseases,1 the launch of the WHO Global Diabetes Compact,2 the World Health Assembly resolution on diabetes3 and the setting of five global diabetes coverage targets.4

Access to quality-assured affordable insulin is crucial to prevent serious complications and early death in people living with diabetes. Access to self-monitoring blood glucose (SMBG) devices is also crucial to ensure insulin treatment achieves glycaemic targets, and hypoglycaemia or hyperglycaemia is prevented. Accessing these devices was recognised by WHO in the target of ‘100% of people with type 1 diabetes have access to affordable insulin and blood glucose self-monitoring’4 and their inclusion in the 2023 list of essential diagnostics.5

Since the 1970s, meters and test strips have been used to self-test blood glucose levels. In 1999, the first continuous glucose monitoring (CGM) device was developed, with systems for self-use first marketed between 2004 and 2006. In 2016, the intermittently scanned glucose monitoring (flash) device expanded the market and broadened methods to SMBG.6 In this paper, flash and CGM devices are referred to as CGMs.

SMBG devices must be available, affordable, quality-assured (accurate, reliable, etc) and appropriately used. While surveys have reported availability, prices and/or affordability of insulin,7,10 few have reported on these indicators for SMBG devices, particularly in low-income and middle-income countries (LMICs). In 2018, Klatman et al11 found in 11 of 15 LMICs, the cost of SMBG exceeded the cost of human insulin. In Tanzania, a 2019 study found over 80% availability of meters and strips for self-use in public and faith-based outlets but only 62% in private pharmacies.12 Median prices ranged from US$16.74 to US$21.46 for a meter and US$0.31 to US$0.35 for a strip, depending on the sector, which was unaffordable for the poor. The greatest contribution to the total treatment cost (human insulin and two tests daily) was the price of the strips.12 In contrast, Yeaw et al reported a strip cost US$0.98 in the USA, and SMBG accounted for 27% of the total treatment cost.13

This article reports findings from surveys in six LMICs, as part of the Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS) Study.14 The primary objective was to assess availability, prices and affordability of SMBG devices. The secondary objective was to compare the cost of monthly self-testing to the cost of treatment with human and analogue insulins.

Methods

Sampling

From March 2022 to May 2023, national facility-based surveys were undertaken in Fiji, Indonesia, Kyrgyzstan, Mali, Peru and Vietnam. Kyrgyzstan, Mali and Peru were included as facilities are regularly monitored within each country as part of the ACCISS Study. This monitoring includes assessing the availability and prices of SMBG devices. Fiji, Indonesia and Vietnam were selected due to their different healthcare systems and population size. Other factors were geographical spread and where partners were experienced in conducting facility-based availability and price surveys.

The WHO/Health Action International (HAI) price survey methodology15 was used to select the regions and outlets sampled. The validated sampling frame proposes surveying six regions, or administrative regions relevant in the country. Within each region, a minimum of five outlets per sector should be surveyed (or less if fewer outlets exist). Online supplemental appendix table 1 lists regions and numbers of outlets sampled per country. All countries surveyed public sector outlets supplying outpatients (such as public hospital dispensaries and clinics) and private retail pharmacies in the community. The number of regions and outlets sampled in each country met the WHO/HAI criteria, except in Mali. Data were also collected from medical device shops in Vietnam (as it was known that people commonly access SMBG devices in these shops); three major online marketplaces in Indonesia (also known to supply SMBG devices). The marketplaces were a mix of regulated and unregulated pharmacy and non-pharmacy sites; and CGM manufacturers selling online directly to individuals in each country.

Products

Availability and retail (patient) prices were collected for all SMBG devices (meters, test strips, lancets and CGMs) found in the outlets. Any lancets supplied for self-use to pierce skin were included, but multifunction meters and strips were excluded. Prices of all insulins, insulin syringes and pen needles in stock were also collected.

Data collection and quality assurance

Data were collected from outlets (public sector dispensaries/clinics, private pharmacies and medical device shops) through in-person visits and then entered into spreadsheets. The exception was Mali where phone interviews were held.

Indonesian online marketplace prices were taken directly from the seller’s website. Where possible, CGM manufacturers were contacted in each country about their online selling prices.

Datasets were checked by national investigators and the lead survey investigator, with anomalies queried and corrected where required.

Data analysis

Availability in each country was assessed as the percentage of outlets per sector that stocked SMBGs on the survey day. The number of brands found per outlet was also assessed. In line with the WHO/HAI methodology, levels of public sector outlets were excluded where the government’s policy does not permit the supply of SMBGs to outpatients. In the brand analyses, no distinction was made between different models of the same brand.

Prices were calculated in US dollars (US$), using the exchange rate on Oanda16 on the first day of data collection. Online supplemental appendix table 1 gives the date of the first day of data collection per country. Minimum, maximum and median unit prices were calculated per sector. Online marketplace prices excluded delivery charges.

The WHO target does not define affordability, so the WHO/HAI threshold of not more than 1 days’ wage to purchase 30 days’ supply was used. This threshold has been widely used in national medicine price and affordability surveys. Affordability was expressed as the number of days the lowest-paid unskilled government worker must work to purchase one meter or 50 test strips, at median prices, or two or four CGM sensors depending on the brand. Where this salary was unknown, the official minimum daily wage was used. Online supplemental appendix table 1 lists the daily wages.

30 days (1-month) supply was used in the comparison of costs for SMBG versus insulin:

  • Meter: 1/24th of the median unit price (it was assumed a meter would last 2 years).

  • Test strips: 150 (considered American Diabetes Association17 and International Society for Pediatric and Adolescent Diabetes (ISPAD)18 recommendation of 6–10 tests a day for people living with type 1 diabetes)

  • Insulin: 600 IU short-acting and 600 IU intermediate-acting human insulins or 600 IU rapid-acting and 600 IU long-acting analogue insulins (based on the defined daily dose of 40 IU/day.19

  • Insulin syringes and pen needles: 60

  • Lancets: 8

Results

Availability

At the time of the study, SMBG devices were generally not provided to outpatients by the governments of Fiji, Indonesia, Kyrgyzstan and Peru. However, some exceptions were found—one outlet in Kyrgyzstan provided free meters and strips for children (donated via WHO) and four outlets in Peru (Junin region) provided free strips.

Meters

Private sector availability of meters ranged from 100% (Fiji) to 31% (Kyrgyzstan) (figure 1). In Mali, meters were not found in the public sector but had 67% availability in the private sector. In Vietnam, availability was highest in medical device shops (100%) and lowest in the public sector (57%). Variation was found across survey regions within countries, for example, availability in Indonesian private pharmacies ranged from 9% in West Kalimantan to 79% in North Sumatra.

Figure 1. Percentage availability SMBG devices in outlets, by country and sector. No CGMs were found in any public sector outlet or private pharmacy in any of the six countries. CGMs, continuous glucose monitoring; DEV, medical device shops; PUB, public sector outlets; PRIV, private pharmacies; SMBG, self-monitoring blood glucose.

Figure 1

Test strips

A similar picture to meters was seen for test strips. Private sector availability ranged from 100% (Fiji) to 39% (Kyrgyzstan) (figure 1). Strips were not found in the public sector in Mali but had 67% availability in private pharmacies. In Vietnam, availability of strips was highest in medical device shops (100%) and lowest in public sector outlets (53%). Variation within countries was found, for example, in Vietnam, test strip availability in private pharmacies was only 40% in Nam Dinh but 80% or higher in the other five regions.

Lancets

Lancets were not supplied for home use in the public sector in Fiji and Kyrgyzstan. Availability was variable in other sectors and countries, from 0% (public sector in Mali) to 100% (private pharmacies in Fiji).

Continuous glucose monitoring

CGM devices were not found in outlets in all six countries. They were sold online in marketplaces in Indonesia, and by manufacturers, also via online sales, in Peru and Vietnam.

Brands of meters

While the majority of private pharmacies in Indonesia, Kyrgyzstan and Mali stocked only one brand of meter, in Fiji and Peru the opposite was found. For example, in Fiji, 91% of the private pharmacies stocked 2–5 brands (most stocked 2 brands), whereas only 9% had 1. Vietnam had the highest number of brands per outlet; 34% of medical device shops and 8% of private pharmacies stocked six or more brands.

In the public sector, excluding the donated products in Kyrgyzstan, the number of brands of meters found ranged from 4 (Indonesia) to 14 (Vietnam). In private pharmacies, they ranged from 1 (Mali) to 19 (Vietnam). In medical device shops (Vietnam) and online marketplaces (Indonesia), the number of brands found was 32 and 23, respectively.

Accu-Chek was the most found brand in private pharmacies in Kyrgyzstan, Mali, Vietnam and Peru. It was also the most found brand sold in online marketplaces in Indonesia. EasyTouch was the most found brand in private pharmacies in Indonesia. In public sector outlets and device shops in Vietnam, the most found brand of meter was OnCall.

See online supplemental appendix table 2 for both meters and strips.

Brands of test strips

The majority of private pharmacies in all countries stocked only one brand of test strip except Fiji (9% had one brand only and 91% had 2–5) and Vietnam (42% had 1 brand 46% had 2–5 and 12% had 6 or more). Vietnam device shops had the highest number of brands of strips in stock; 66% had 2–5 and 34% had 6 or more. In public sector outlets in Vietnam, 50% had 1 brand of strip in stock and 50% had 2–5.

Across the public sector in each country, the largest number of test strip brands found was 14 (Vietnam). In private pharmacies, the number of brands found ranged from 1 (Mali) to 19 (Vietnam). In Vietnam device shops and Indonesian online marketplaces, the number of brands found was 23 and 20, respectively.

In private pharmacies, a positive link was found between the availability of brand-matched test strips to meters. In Fiji, Peru and Mali all private pharmacies that stocked meters also stocked the same brand of strips. In Indonesia, Vietnam and Kyrgyzstan, the percentage of pharmacies where strips were in stock for all the brands of meters stocked was 89%, 80% and 73%, respectively. In Vietnam, two of the six medical device shops had brand-matched strips to all the meters in stock.

Accu-Chek was the most found brand in both sectors in Peru, private pharmacies in Kyrgyzstan, Mali and Vietnam and device shops in Vietnam. OneTouch was the most common brand in the public sector in Vietnam, GES and EasyTouch in online marketplaces and private pharmacies in Indonesia, respectively. In Fiji, CareSens and CodeFree meters and strips dominated the market.

Retail prices

Meters

Median prices for a meter, purchased in private pharmacies, ranged from US$15.62 (Kyrgyzstan) to US$35.18 (Vietnam) (see figure 2). The greatest price variation was seen in Indonesian online marketplaces (from US$3.13 to US$131.19), however, the median price (US$18.37) was lower than in Indonesian private pharmacies (US$23.90). There were large price variations in Vietnam, but the median price was identical (US$35.18) in the three sectors.

Figure 2. Retail prices, in US$, for one meter by country and sector. DEV, medical device shops; ONL, online marketplaces; PRIV, private pharmacies; PUB, public sector outlets.

Figure 2

Test strips

Median prices for one test strip in private pharmacies ranged from US$0.28 (Kyrgyzstan) to US$0.56 (Mali), see figure 3. There were large differences between minimum and maximum prices in Indonesia, Vietnam and Peru. As with meters, the greatest price variation was seen in Indonesian online marketplaces (from US$0.09 to US$0.96), with the median price 20% lower (US$0.27) than in private pharmacies (US$0.34).

Figure 3. Retail prices, in US$, for one test strip by country and sector. DEV, medical device shops; ONL, online marketplaces; PUB, public sector outlets; PRIV, private pharmacies.

Figure 3

Lancets

In the public sector where lancets are provided for home use and people have to pay, median unit prices were US$0.03 (Vietnam) and US$0.05 (Indonesia). In private pharmacies, prices ranged from US$0.02 to US$0.20 in Indonesia and Mali, respectively. Unlike meters and strips, in Vietnam median prices for lancets were higher in device shops (median US$0.07) than in the public (US$0.03) and private (US$0.04) sectors. The Indonesian online marketplace median price was identical to private pharmacies (US$0.02) but less than in the public sector (US$0.05).

Continuous glucose monitoring

No manufacturers were found to be supplying CGMs online to people in Fiji, Mali and Kyrgyzstan. In Vietnam, Medtronic Guardian was for sale online at US$1979 for a transmitter, US$70 for an inserter and US$88 for one sensor (duration 7 days). Medtronic also operated a rental scheme and supplied free of charge to low-income people when referred by a hospital. In Peru, Abbott Freestyle Libre 1, was sold online at US$67 for a reader or one sensor (duration 14 days). Abbott Freestyle Libre was also for sale in Indonesian online marketplaces at median prices of US$107 (range US$64–US$279) for a reader and US$107 (range US$69–US$$342) for one sensor.

In Kyrgyzstan, a company selling medical equipment online had Abbott and Medtronic sensors for sale at US$75 and US$50, respectively. They also sold Medtronic transmitters for US$650 each.

Online supplemental appendix table 3 summarises median unit prices for a meter, strip, lancet and CGM sensor by country and sector (where found).

Affordability

Where people pay out-of-pocket (OOP), the lowest-paid unskilled government worker requires between 1.5 (Fiji) to 10.9 (Mali) days’ wages to purchase one meter (at median prices), depending on the country and sector. 50 test strips required from 1 (Fiji) to 12.8 (Mali) days’ wages (see online supplemental appendix figure 6).

A month’s supply of CGM sensors (excluding readers and transmitters) purchased online from manufacturers in Peru and Vietnam required 15 and 65 days’ wages, respectively. The sensors were far less affordable than 150 test strips (excluding a meter), which required 8 days’ wages in Peru (purchased from private pharmacies) and 8.3 or 9.5 days’ wages in Vietnam (from private pharmacies and device shops, respectively). A similar picture was seen in Indonesia, where sensors purchased from the online marketplaces required 61 days’ wages for 30 days’ supply, whereas 150 strips required 11.4 and 14.4 days’ wages from online marketplaces and private pharmacies, respectively.

Prices and affordability of self-monitoring versus insulin treatment

Based on median prices and five tests daily, prices and affordability for 30 days’ supply (using human insulin in vials) are shown in figure 4. In all cases, the greatest contribution to the total price was the test strips.

Figure 4. Prices and affordability for 30 days supply of total treatment—human insulin vials. (1) Insulin from public sector (free); devices from private pharmacies (OOP payment). (2) Insulin and syringes from public sector (free); other devices available only in private sector (OOP). (3) Insulin OOP for people without social insurance; devices OOP (whether people covered by social insurance or not). (4) Insulin from private pharmacies OOP for people without social insurance; devices OOP from device shops. DEV, medical device shops; FJ, Fiji; KG, Kyrgyzstan; ML, Mali; OOP, out-of-pocket; PE, Peru; PRIV PHY, private pharmacy; PUB, public sector outlets; VN, Vietnam.

Figure 4

When using analogue insulin in prefilled pens, a mixed picture was seen (figure 5). In private pharmacies in Fiji, Peru and Vietnam, and online marketplaces in Indonesia, testing cost less than analogues and pen needles. The opposite was seen in private pharmacies and the mixed public/private pharmacies in Indonesia, and in Vietnam when testing devices were purchased from device shops and analogue insulin from private pharmacies.

Figure 5. Prices and affordability for 30 days supply of total treatment—analogue insulin pens. This analysis excluded analogue insulin in vials. (1) Insulin and pen needles from public sector (free); other devices available only in private sector (OOP). (2) Insulin and pen needles from public sector OOP for people without JKN coverage; other devices available only in private sector with OOP payment for people with and without JKN. (3) Insulin OOP for people without social insurance; devices all OOP (whether covered by social insurance or not). (4) Insulin from private pharmacies OOP for people without social insurance; devices all OOP from device shops. DEV, medical device shops; FJ, Fiji; ID, Indonesia; JKN, Jaminan Kesehatan Nasional; KG, Kyrgyzstan; ML, Mali; ONLINE, online marketplaces; OOP, out-of-pocket; PE, Peru; PRIV PHY, private pharmacy; PUB, public sector outlets; VN, Vietnam.

Figure 5

Whether using human or analogue insulin, affordability of insulin and self-monitoring was poor in all countries and sectors, ranging from 4 to nearly 50 days’ wages for people on a low wage.

Discussion

This study shows the costs of testing using SMBG devices, and how this significantly adds to the cost of treatment for people living with diabetes. Government policies and practices for the supply of meters and strips (and insulin) varied in the study countries, and no governments or private pharmacies supplied CGMs.

Insulin is provided free of charge in Kyrgyzstan. Since mid-2024, 800 and 2500 test strips for adults and children/teenagers, respectively, are provided annually at no charge as part of the State Guaranteed Benefits Package. Insulin is also provided free of charge in Indonesia and Vietnam for individuals with social health insurance. In Fiji, human insulin is free for people on low wages as part of the ‘Free Medicines Scheme’. However, in these countries, SMBG devices must be purchased OOP. We found SMBG devices were unaffordable. However, this was not the case in Fiji where meters and strips were both available and affordable in private pharmacies.

Indonesia has advanced Universal Health Coverage (UHC) by merging smaller, fragmented health insurance schemes into a single universal scheme for all Indonesian citizens, called the Jaminan Kesehatan Nasional (JKN).20 Under the JKN scheme, a mix of public and private providers deliver health service benefits.20 In 2022, 90% of the population were covered by JKN. The scheme covers all medicines, including insulin, for inpatients and outpatients.20 However, the scheme does not cover SMBG devices for outpatients (inpatients are reimbursed as part of case-based payments). Availability of SMBG devices in private pharmacies was suboptimal, and prices were unaffordable (requiring nearly 5 days’ wages to purchase 50 strips). Meters and strips were also unaffordable when purchased at median prices from online marketplaces, although there was a wide range of prices.

In Vietnam, social health insurance provides coverage for 92% of the population (2023).21 Insulin is provided free of charge but not SMBG devices. This study found meters and strips had good availability in private pharmacies and medical device shops, but not in public sector facilities where availability was less than 60%. SMBG devices were unaffordable, requiring nearly 1 weeks’ wages to buy 1 meter and 3 days’ wages for 50 strips (based on median prices).

In Mali, government policy is to supply meters, strips and insulin to outpatients but none of these were found in public sector outlets. In private pharmacies, availability was 67%, however, purchasing 1 meter and 50 strips required 11 and 13 days’, wages respectively.

In Peru, the health system is both segmented—into public and private sectors—and fragmented across various provider institutions and insurance schemes.22 Each sector and insurance scheme is distinct, with its own mechanisms for procuring and supplying medicines and medical devices. Public institutions that operate under government-subsidised health insurance provide essential medicines free of charge (including human insulin). However, there are currently no guidelines for the provision of self-use medical devices, such as glucose meters and strips. Public institutions under the Social Security insurance may provide certain medical devices free of charge, but availability varies by region. We found that meters and strips were available and provided free of charge in Social Security facilities in only one region (Junin). Private pharmacy prices in Peru were unaffordable, requiring 3–4 days’ wages to purchase 1 meter or 50 strips.

In four of the six countries, the majority of private pharmacies stocked only one brand of meter and test strips. While stocking the identical brand of meter and strip eliminates compatibility issues for those purchasing both, it can have negative consequences for individuals who might already own a different brand of glucose meter and are looking to purchase compatible strips. Further, it limits people’s choice of brand and price and will compromise use if the brand does not meet quality standards.

Across the countries and sectors, the largest price variation for both meters and strips was found in the online marketplaces in Indonesia, private pharmacies in Peru and medical device shops in Vietnam. This may be the result of competition in Indonesia and Vietnam, where a large number of sellers and/or brands were found. The reason for the large price variation in Peruvian private pharmacies is unclear but may be a consequence of the lack of price controls and/or unregulated mark-ups.

CGMs were unavailable in the public sector and private pharmacies sampled in this study. But they were purchasable from manufacturers in some countries and from online marketplaces in Indonesia. Prices were very high and unaffordable, particularly for sensors (2–4 are needed per month depending on the brand). The Cost of Goods Sold (COGS) of one Abbott Freestyle Libre 2 sensor is estimated to be US$8.2–US$10.3, and up to 34% lower for Libre 3.23 Selling prices found in this study for Freestyle Libre (US$67 and over) far exceeded the COGS.

In wealthier countries the price of CGM sensors can also be high. In New Zealand, for example, the government only recently agreed to fund CGMs, paying US$49 (Dexcom ONE) and US$56 (Abbott Freestyle Libre 2) for one sensor.24 Meanwhile, in the USA, Veterans Affairs paid from US$52 to US$58 per sensor.25

In LMICS, limited availability and high OOP prices will impact the use of CGMs. Beyond price and availability factors, evidence on use and value of CGMs is limited, therefore, in many LMICs, there remains a lack of context-specific, evidence-based policies on the use of CGMs.26

The role of online sellers when purchasing SMBG devices was evident in Indonesia. People can benefit from buying from these marketplaces as they sell more brands, median prices were lower compared with private pharmacies (although delivery costs may be added), and they could shop around for a required brand without having to travel to outlets. However, some sellers are unregulated so quality may not be assured. Additionally, some online prices were higher than those found in private pharmacies. No CGMs have marketing authorisation in Indonesia, however, they were available for sale in the online marketplaces.

This study was conducted in LMICs. In high-income countries, SMBG devices (including CGM sensors) are more likely to be found in private pharmacies and may be subsidised by the government or included in insurance policies. However, prices are not always lower, even when the government is the major buyer in the country. In the UK, the National Health Service Drug Tariff price for one strip ranged from US$0.14 to US$0.43 depending on the brand.27 In New Zealand, only one brand was funded (CareSens) at a price of US$0.13 a strip.24 US Veterans Affairs prices ranged from US$0.10 to US$0.70 a strip.25

When SMBG devices are not provided by governments in adequate quantities either for free or at affordable prices, or when availability is suboptimal, people are forced to purchase in other sectors. While purchasing a glucose meter is a one-off payment, the price can be far beyond a person’s ability to pay. Further, strips must be purchased on an ongoing basis, and the price per strip and number needed per day can make them unaffordable. While OOP payments for SMBG devices can be an economic burden for many people, they especially impact the poor who rely on the public sector to provide affordable diabetes treatment. This inability to pay for SMBG devices can result in people compromising, or forgoing, self-testing which can impact an individual’s overall diabetes management.

Governments need to include SMBG devices in their diabetes treatment package as part of UHC. Some LMICs have adopted policies in recent years to include the provision of SMBG devices, as noted above for Kyrgyzstan. Another example is South Africa where the government provides between 50 and 150 strips per month (up to 200 for children on motivation) for people using insulin. It is crucial that the number of strips provided is sufficient to meet frequent testing needs. Education is also needed on the importance of regular testing and how to adjust insulin doses based on the readings.

Governments also need to ensure regular, independent and transparent monitoring of the availability, prices and affordability of SMBG devices (and insulin) in facilities and households, plus the number of self-tests undertaken per day. Diabetes groups/organisations and independent research organisations in-country could undertake the monitoring, in collaboration with the Ministry of Health. An option to implement facility and household monitoring is the use of HAI’s MAIn (Monitoring Access to Insulin) tool.28 The findings from monitoring would inform the development of national and global policies and practices that improve self-management for people living with diabetes.

Manufacturers of SMBG devices (and insulin) also have a role in improving access. Manufacturers revenue is driven primarily by strips (97%) rather than meters (1%) and lancets (2%).29 To increase sales, manufacturers may limit the compatibility of their strips to their meters, so strips do not work with other meter brands or with different models of the same brand.29 Manufacturers may provide meters for free to encourage people to switch to their brand. Although more costly to manufacture than strips, these manufacturers are willing to absorb the cost of free meters given the potential for strip sales.29 These marketing practices add to the challenges of self-testing. On the other hand, a highly competitive landscape puts downward pressure on prices, forcing established brands to reconsider their prices and encouraging innovation in cost-effective solutions. An example is the launch of a meter-free test strip, where a mobile phone app is used to obtain glucose readings (thus eliminating the need to purchase a meter). While this solution is currently limited to people with type 2 diabetes, the approach may evolve in the future to include all types of diabetes.30

As part of the WHO’s Global Diabetes Compact, in 2021 WHO formulated 31 ‘asks’ of industry aimed at strengthening their commitment and contribution to improved access to quality, safe and affordable insulin and devices in LMICs.31 The asks are directed towards global policies and activities where the manufacturers are largely responsible, such as innovation, intellectual property, marketing and pricing. To date, there has been no reporting of industry progress in achieving the asks.

Limitations

Study limitations included the small sample size in Mali (so the findings cannot be considered representative of the country). In Indonesia, only three online marketplaces were sampled so they do not represent all online sales channels accessible to the public. Additional limitations include the scant data on CGM prices, and that availability only refers to the day of data collection. In this study, affordability was based on the daily wage of the lowest-paid unskilled government worker. In many countries, a substantial proportion of the population earns less than this amount.32 Also impacting affordability is the number of test strips used in the analysis. We used five strips per day, however, organisations can differ in their recommended number of tests per day.17 18 33

Conclusions

SMBG is an integral component of diabetes management, as recognised by the WHO in their target of 100% access to affordable insulin and blood-glucose self-monitoring.4 However, in many LMICs access to these essential devices remains poor and is a barrier to diabetes care.34 While more research is needed to improve understanding on the benefits and value of CGMs in LMICs, improved access to glucose meters and test strips must be addressed now and not considered in isolation to access to insulin.35

Governments must supply SMBG devices either free of charge (in quantities that meet people’s needs) or at affordable prices for all. In the private sector, prices must be controlled. Without these actions, people will compromise or forgo glucose testing. This can result in serious health consequences for the individual and healthcare funding issues for governments. Regular household and facility monitoring is needed to assess the availability, prices and affordability of SMBG devices (and insulin and delivery devices), plus the number of self-tests undertaken.

Test strips need investigation, including the COGS, government procurement prices and volumes, and price components (mark-ups, taxes, etc) in supply chains. The development of new glucose self-monitoring technologies must not only take into account the desired attributes required by people in LMICs,36 but also be affordable in resource-constrained settings.

Supplementary material

online supplemental file 1
bmjph-3-1-s001.pdf (48.4KB, pdf)
DOI: 10.1136/bmjph-2024-001128
online supplemental file 2
bmjph-3-1-s002.pdf (148.9KB, pdf)
DOI: 10.1136/bmjph-2024-001128
online supplemental file 3
bmjph-3-1-s003.pdf (77.6KB, pdf)
DOI: 10.1136/bmjph-2024-001128
online supplemental file 4
bmjph-3-1-s004.pdf (447.8KB, pdf)
DOI: 10.1136/bmjph-2024-001128

Acknowledgements

The authors are very grateful to the people in each country who collected the data, and to the staff in the outlets who so willingly provided it.

The analysis included in this paper is that of the authors alone and does not necessarily reflect the views of the Helmsley Charitable Trust and FIND. All references and conclusions are intended for educational and informative purposes and do not constitute an endorsement or recommendation from the Helmsley Charitable Trust or FIND.

Footnotes

Funding: This study was co-funded by The Leona M. and Harry B. Helmsley Charitable Trust (Grant Number G-2302-06660) and by FIND through a grant from the German Federal Ministry for Education and Research (Grant Number KFW-TBBU02).

Provenance and peer review: Not commissioned; externally peer reviewed.

Patient consent for publication: Not applicable.

Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

online supplemental file 1
bmjph-3-1-s001.pdf (48.4KB, pdf)
DOI: 10.1136/bmjph-2024-001128
online supplemental file 2
bmjph-3-1-s002.pdf (148.9KB, pdf)
DOI: 10.1136/bmjph-2024-001128
online supplemental file 3
bmjph-3-1-s003.pdf (77.6KB, pdf)
DOI: 10.1136/bmjph-2024-001128
online supplemental file 4
bmjph-3-1-s004.pdf (447.8KB, pdf)
DOI: 10.1136/bmjph-2024-001128

Data Availability Statement

All data relevant to the study are included in the article or uploaded as supplementary information.


Articles from BMJ Public Health are provided here courtesy of BMJ Publishing Group

RESOURCES